ライフサイエンスコーパス: virus attachment

1 9-201 and 212-216, independently involved in virus attachment.

2 he viral attachment protein, interfered with virus attachment.

3 ate each of the three amino-terminal HBDs in virus attachment.

4 ed that specific polar lipids may facilitate virus attachment.

5 tralization was not associated with blocking virus attachment.

6 fically blocked HCV entry but did not affect virus attachment.

7 face sialic acid groups for transduction and virus attachment.

8 ation, consistent with a role for CD81 after virus attachment.

9 and that it, like other polyanions, inhibits virus attachment.

10 xsackie/adenovirus receptor (CAR) needed for virus attachment.

11 equire viral lysis, aggregation, or blocking virus attachment.

12 determined to be manifested at the level of virus attachment.

13 omplex did block entry even when added after virus attachment.

14 with cell surface glycosaminoglycans during virus attachment.

15 Virus attachment also induced tyrosine phosphorylation o

16 strate that RBD has two functions: mediating virus attachment and activating the fusion mechanism.

17 de has potential value as a reagent to study virus attachment and as a future therapeutic.

18 This interaction seems to be independent of virus attachment and cell entry.

19 B does not affect gC-dependent mechanisms of virus attachment and does not block virus attachment at

20 extracellular domain is sufficient to permit virus attachment and entry and that the presence of a GP

21 ce glycoprotein (GP1,2) that is required for virus attachment and entry into cells.

22 otein receptor (LDLr) has been implicated in virus attachment and entry into cells.

23 is involved in several functions, including virus attachment and entry to target cells, production o

24 de of HIV-1 infection occurs at the level of virus attachment and entry via a unique mechanism that i

25 titis C (HCV) E2 glycoprotein is involved in virus attachment and entry, and its structural organizat

26 n of ECA11 encoding proteins associated with virus attachment and entry, cytoskeletal organization, a

27 ecific antibodies blocking distinct steps of virus attachment and entry, rather than the perspective

28 ons in both virus and receptor important for virus attachment and entry.

29 l envelope glycoprotein (GP) responsible for virus attachment and entry.

30 d region in the BA strain G protein augments virus attachment and fitness.

31 y gp120 (Env), a viral protein that mediates virus attachment and fusion to target cells, and also fa

32 that MMTV/TLR4 interaction is independent of virus attachment and fusion.

33 binding to hematopoietic cells, we analyzed virus attachment and gene delivery to CHO cells expressi

34 ster cells became susceptible to coxsackie B virus attachment and infection.

35 ate and this type of interaction facilitates virus attachment and infectivity.

36 es bind RSV F protein, which plays a role in virus attachment and mediates fusion.

37 while functional domains are responsible for virus attachment and membrane fusion.

38 role in immunity to measles by blocking both virus attachment and subsequent fusion with the host cel

39 Virus attachment and subsequent infection of polarized c

40 o analyze membrane fusion events that follow virus attachment and to identify multiple epitopes on VZ

41 complex and insights into the mechanisms of virus attachment and uncoating.

42 cluding reverse transcriptase, protease, and virus attachment, and exhibit no detectable activity aga

43 nisms of virus attachment and does not block virus attachment at 4 degrees C.

44 n early role, uncoating assays showed normal virus attachment but delayed virus entry in the absence

45 When proteasome inhibitors were added after virus attachment, early gene expression was prolonged an

46 CD46 mediates virus attachment, entry, and virus-induced cell-to-cell

47 The presence of this efficient virus attachment factor on multiple endothelial cell typ

48 ve contributions of these previously defined virus attachment factors to HIV binding and accumulation

49 Virus attachment, fusion, internalization and transport

50 A Hendra virus attachment (G) glycoprotein subunit vaccine was te

51 must be present during the initial phase of virus attachment; in contrast, addition of galectin-1 po

52 We found that influenza virus attachment induced PI3K-dependent FAK-Y397 phospho

53 iously disclosed HIV (human immunodeficiency virus) attachment inhibitors, exemplified by BMS 806 (fo

54 idase (HN) protein, which is responsible for virus attachment, interacts with the fusion protein in a

55 CD34(+) cells and K562 cells on the level of virus attachment, internalization, and replication.

56 With the caveat that virus attachment is only the first step in the virus rep

57 Integrin alphavbeta6 is the major site for virus attachment on the beta6-transfected cells, and bin

58 ever, HCMV gB is not absolutely required for virus attachment or assembly and egress from infected ce

59 Abeta enhanced infection at the stage of virus attachment or entry into the cell.

60 h palivizumab or motavizumab did not inhibit virus attachment or the ability of F protein to interact

61 ainst HIV-1 reverse transcriptase, protease, virus attachment, or nucleocapsid protein zinc fingers.

62 ences described to the S RNA, containing the virus attachment protein glycoprotein 1.

63 ted potential interface areas of the measles virus attachment protein hemagglutinin to begin the inve

64 Virus attachment proteins mediate binding to host cell r

65 B Ad fiber knobs that use CD46 as a primary virus attachment receptor.

66 RGD motif in the penton base did not affect virus attachment, regardless of the type of cellular rec

67 fluenza viruses were labeled to identify the virus attachment site in the mouse cornea.

68 Neither the initial virus attachment site, heparan sulfate proteoglycans, no

69 internalization, but functions merely as the virus attachment site, suggests that the extracellular p

70 Membrane proteins that mediate virus attachment tether virus particles to the cell surf

71 HIV-1 Env mediates virus attachment to and fusion with target cell membrane

72 genome size did not affect the efficiency of virus attachment to and internalization into cells.

73 anti-gp120 mAb IgGb12, an agent that blocks virus attachment to CD4, suggesting that endocytosed vir

74 Infection would proceed through virus attachment to cell surface heparan sulfate (HS) pr

75 eased sensitivity to GAG-based inhibitors of virus attachment to cells and reduced release of viral p

76 Virus attachment to cells plays an essential role in vir

77 t the antibody neutralizes HAstV by blocking virus attachment to cells.

78 0 and the protein itself did not inhibit the virus attachment to cells.

79 that the duplicated region functions during virus attachment to cells.

80 ould largely be explained by competition for virus attachment to cellular CD4 rather than other detri

81 determining viral persistence by influencing virus attachment to cellular receptors, such as sialylol

82 Although we found abundant H7 virus attachment to corneal epithelial tissue, this did

83 Here, we report that virus attachment to DAF on the apical cell surface activ

84 compared MV protein A27, which has a role in virus attachment to glycosaminoglycans on the cell surfa

85 to these glycoproteins, such as gC-mediated virus attachment to heparan sulfate or gE-mediated cell-

86 te that HSV-1 exploits galectin-3 to enhance virus attachment to host cells and support a protective

87 we provide evidence that the antibody blocks virus attachment to human cells.

88 h larger amino acids specifically eliminated virus attachment to human DAF but had no effect on attac

89 rnalization into epithelial cells as well as virus attachment to monocytic cells.

90 epends on intracellular signals triggered by virus attachment to PVR.

91 2161 and G2174 are directly involved in BeAn virus attachment to sialic acid and that substitutions o

92 expected for a process limited by ecotropic virus attachment to single receptors, fusion-from-withou

93 ng activity similar to that observed for KOS virus attachment to sog9 cells, a glycosaminoglycan-defi

94 with resistance to symptomatic infection and virus attachment to such motifs is essential to the infe

95 The specificity of virus attachment to target cells is mediated by hemagglu

96 al neutralization, heterotypic immunity, and virus attachment to target cells.

97 While gD has at least two functions, virus attachment to the cell and initiation of the virus

98 chronically infected cells or reduce initial virus attachment to the cell membrane.

99 of uncoating but had little or no effect on virus attachment to the cell surface.

100 to the immobilized GAG brushes ensures firm virus attachment to the interface.

101 to cause pneumonia, which is associated with virus attachment to the lower respiratory tract.

102 while polyclonal sera can specifically block virus attachment to the receptor.

103 ssion among humans, which is associated with virus attachment to the upper respiratory tract.

104 DC-SIGN was required for virus attachment to these cells and DC-SIGN-expressing c

105 rminus of the G protein is also required for virus attachment to this model of the in vivo target cel

106 virus infection, and it does so by blocking virus attachment to TIM1.

107 ese interactions determine the mechanisms of virus attachment, uptake, intracellular trafficking, and

108 entry into host cells is directly linked to virus attachment via CD81 for HCV, this step in the vira

109 -targeting inhibitors typically act prior to virus attachment, whereas gp41 inhibitors are able to ac

110 s due to lower affinity of luminal cells for virus attachment, which can be overcome by pretreating c